Table 2.
Stepwise Multivariate Analysis of Disease-Free Survival for All Cases and for Luminal A and Luminal B
| Characteristic | Hazard Ratio | 95% CI | P |
|---|---|---|---|
| All cases | |||
| TAC treatment | 0.73 | 0.58 to 0.91 | .0051 |
| Tamoxifen treatment | 0.41 | 0.31 to 0.56 | < .0001 |
| Tamoxifen* triple negative | 4.01 | 2.00 to 8.05 | < .0001 |
| Tamoxifen* HER2 | 2.56 | 0.95 to 6.93 | .0633 |
| Tamoxifen* luminal A | 0.56 | 0.34 to 0.93 | .0257 |
| Triple negative | 0.62 | 0.43 to 0.90 | .0124 |
| HER2 | 0.65 | 0.42 to 1.02 | .0602 |
| Tumor size > 2 cm | 1.33 | 1.05 to 1.69 | .0178 |
| Histologic subtype | 1.39 | 0.99 to 1.96 | .0612 |
| Grade 3 | 1.39 | 1.07 to 1.80 | .0137 |
| Vascular invasion | 1.34 | 1.06 to 1.69 | .0141 |
| 4-9 positive nodes | 1.87 | 1.46 to 2.40 | < .0001 |
| 10+ positive nodes | 3.09 | 2.23 to 4.27 | < .0001 |
| Luminal B | |||
| TAC treatment | 0.71 | 0.53 to 0.95 | .022 |
| Tamoxifen treatment | 0.44 | 0.32 to 0.61 | < .0001 |
| Tumor size > 2 cm | 1.49 | 1.10 to 2.02 | .011 |
| Histologic subtype | 1.62 | 1.06 to 2.49 | .027 |
| 1-3 positive nodes | 1.98 | 1.46 to 2.67 | < .0001 |
| 4-9 positive nodes | 1.61 | 1.15 to 2.26 | .005 |
| 10+ positive nodes | 4.33 | 2.93 to 6.41 | < .0001 |
| Luminal A | |||
| TAC treatment | 0.97 | 0.46 to 2.06 | .943 |
| Tamoxifen treatment | 0.15 | 0.07 to 0.33 | < .0001 |
| 4-9 positive nodes | 4.30 | 1.81 to 10.20 | .001 |
| 10+ positive nodes | 5.11 | 1.82 to 14.37 | .002 |
NOTE. Variables involved in the definition of biologic subtypes were not included in this model.
Abbreviation: TAC, docetaxel, doxorubicin, cyclophosphamide.